EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Two‐year outcomes of epicranial focal cortex stimulation in pharmacoresistant focal epilepsy

Andreas Schulze-Bonhage iD, Martin Hirsch iD, Susanne Knake, Ann Mertens iD, Michael Rademacher, Elisabeth Kaufmann iD, Josua Kegele iD, Carolin Jenkner, Volker Coenen, Martin Glaser, Sergiu Groppa, Yaroslav Winter iD und 1 weitere

Epilepsia · 2025-09 · 66 (9) · 3242-3253

DOI: 10.1111/epi.18448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 16.05.2025. Verfasst von Andreas Schulze-Bonhage und 12 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Center, University Medical Center, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Epilepsies, Partial, Cerebral Cortex, Deep Brain Stimulation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung), Precisis, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to report on the long‐term safety and efficacy of epicranial focal cortex stimulation (FCS) using the EASEE device as adjunctive neuromodulatory therapy in improving seizure control in adults with pharmacoresistant epilepsy originating from one predominant epileptogenic zone.

Methods

Prospective open‐label follow‐up of patients from the EASEE II and PIMIDES I clinical trials was done for a period of 2 years after the epicranial implantation of the EASEE electrode and stimulator device.

Results

Thirty‐three patients underwent device implantation, and stimulation was activated in 32 patients. Of these, 26 patients continued stimulation up to 2‐year follow‐up and provided seizure diary data for efficacy analysis. The 50% responder rate at 2‐year follow‐up was 65.4% (95% confidence interval = 44.3–82.8), corresponding to a median seizure frequency reduction of 68%. Patients reported improved health‐related quality of life. Tolerability was excellent, and there were no severe adverse events considered to be related to implantation or stimulation, nor were adverse effects on mood or cognition reported. Significance Results of the 2‐year follow‐up show that epicranial FCS is well tolerated by patients while providing improved seizure control in the long term. It thus offers a minimally invasive treatment option for patients with a predominant epileptic focus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyEpilepsies, PartialCerebral CortexDeep Brain StimulationHumansMaleFemaleAdultTreatment OutcomeMiddle AgedYoung AdultFollow-Up StudiesProspective StudiesQuality of LifeElectrodes, ImplantedAdolescent

Stichwörter der Autor:innen

epileptic focusfocal epilepsylong‐term outcomeneuromodulationneurostimulation

Autor:innen und Institutionen

  • Epilepsy Center, University Medical Center, University of Freiburg, Freiburg, Germany.
  • NeuroModul Basic, University of Freiburg, Freiburg, Germany.
  • Bernstein Center of Computational Neuroscience, University of Freiburg, Freiburg, Germany.
  • European Reference Network EpiCARE, Lyon, France.
  • Neurology, University Hospital Marburg, Marburg, Germany.
  • Neurology, University Hospital Gent, Ghent, Belgium.

ORCID-Profile: Andreas Schulze-Bonhage, Martin Hirsch, Ann Mertens, Elisabeth Kaufmann, Josua Kegele, Yaroslav Winter

Förderung

  • German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung)
  • Precisis
  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Schulze-Bonhage, A., Hirsch, M., Knake, S., Mertens, A., Rademacher, M., Kaufmann, E., Kegele, J., Jenkner, C., Coenen, V., Glaser, M., Groppa, S., Winter, Y., & EASEE Study Group (2025). Two‐year outcomes of epicranial focal cortex stimulation in pharmacoresistant focal epilepsy. Epilepsia, 66(9), 3242-3253. https://doi.org/10.1111/epi.18448

Vancouver

Schulze-Bonhage A, Hirsch M, Knake S, Mertens A, Rademacher M, Kaufmann E, et al. Two‐year outcomes of epicranial focal cortex stimulation in pharmacoresistant focal epilepsy. Epilepsia. 2025;66(9):3242-3253. doi:10.1111/epi.18448

BibTeX
@article{SchulzeBonhage2025,
  author = {Schulze-Bonhage, Andreas and Hirsch, Martin and Knake, Susanne and Mertens, Ann and Rademacher, Michael and Kaufmann, Elisabeth and Kegele, Josua and Jenkner, Carolin and Coenen, Volker and Glaser, Martin and Groppa, Sergiu and Winter, Yaroslav and EASEE Study Group, EASEE Study Group},
  title = {Two‐year outcomes of epicranial focal cortex stimulation in pharmacoresistant focal epilepsy},
  journal = {Epilepsia},
  year = {2025},
  volume = {66},
  number = {9},
  pages = {3242--3253},
  doi = {10.1111/epi.18448}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche